Complex syndromes of chronic pain, fatigue and cognitive impairment linked to autoimmune dysautonomia and small fiber neuropathy.
Shoenfeld, Yehuda, Ryabkova, Varvara A, Scheibenbogen, Carmen et al. · Clinical immunology (Orlando, Fla.) · 2020 · DOI
Quick Summary
This review brings together evidence suggesting that ME/CFS, along with related conditions like POTS and complex regional pain syndrome, may share a common autoimmune root cause. The researchers found that these conditions are linked by similar patterns: the body's immune system produces antibodies that attack certain nerve receptors, and small nerve fibers become damaged. By understanding these shared mechanisms, doctors may eventually be able to better identify which patients would benefit from immune-targeting treatments.
Why It Matters
This work provides a conceptual bridge linking ME/CFS to measurable immunological abnormalities and small fiber neuropathy, potentially validating long-standing patient reports of real physiological dysfunction. If the proposed autoimmune subgroup exists, it could enable stratification of ME/CFS patients for targeted immunotherapy trials, moving beyond one-size-fits-all treatment approaches.
Observed Findings
Multiple syndromes (ME/CFS, POTS, CRPS, silicone implant syndrome) show evidence of autoantibodies targeting G-protein coupled receptors
Small fiber neuropathy is documented across these four conditions
Autoimmune comorbidities and altered immune cell subsets are reported in these patient populations
Animal models support autoimmune mechanisms in some of these syndromes
Sjögren's syndrome shares immunological patterns with the four syndromes examined
Inferred Conclusions
An autoimmune neurosensory dysautonomia subgroup exists across these four traditionally separate syndromes
Autoantibodies against G-protein coupled receptors may be a common pathogenic denominator
Small fiber neuropathy serves as a shared structural/functional hallmark in this disease cluster
Identifying the autoimmune subgroup could enable targeted immunotherapy approaches in appropriate patients
Remaining Questions
What proportion of ME/CFS patients belong to this autoimmune subgroup versus other pathophysiological subtypes?
Do specific autoantibody profiles predict treatment response to immunotherapy in these conditions?
What This Study Does Not Prove
This review does not prove that autoimmunity causes ME/CFS in all patients—only that an autoimmune subset may exist. It does not establish treatment efficacy or safety of any immunotherapy for these conditions. The unifying concept remains theoretical and requires prospective clinical validation before clinical application.